newsfilter
← Latest News
Business Wire·

MindWalk Holdings Corp. Reports Fiscal 2026 Results: Revenue Up 46% as the Company Completes Its Pivot to Bio-Native AI Infrastructure

HYFT
  • MindWalk Holdings Corp. reported full-year 2026 revenue of $15.6 million CAD, a 46% increase from the prior year, with gross margin expanding to 59%.
  • The company's net loss narrowed by more than 50% to $13.9 million CAD from $30.2 million CAD in fiscal 2025.
  • Total operating expenses decreased by 44% to $24.1 million CAD, primarily driven by the non-recurrence of $22.7 million CAD in prior-year non-cash amortization & impairment charges.
  • MindWalk divested its Netherlands subsidiary, ImmunoPrecise Antibodies (Europe) B.V., to AVS Bio in August 2025, generating approximately $14.3 million CAD in proceeds.
  • The company secured its first contracted, recurring enterprise agreements for its LensAI platform during the fiscal year.
  • Fiscal 2026 marked the completion of MindWalk's transition from building technology to deploying it, focusing on its BioIntelligence infrastructure.
  • MindWalk regained Nasdaq listing compliance organically without utilizing a reverse split or dilutive financing.
  • The company authorized a discretionary share repurchase program for up to 2.3 million common shares, representing approximately 5% of outstanding shares.
  • Commercial launch of the ReefIQ™ platform occurred in June 2026 to expand the BioIntelligence biological context layer.
  • MindWalk was added to the Russell 3000E & Russell Microcap Indexes effective June 26, 2026, following a European patent application filing in June 2026.
  • Fourth quarter 2026 revenue reached $4.1 million CAD, a 50% year-over-year increase, with gross margin improving to 60.6%.
  • Research & development expenses rose to $4.9 million CAD & sales & marketing expenses increased to $5.9 million CAD to support development initiatives & commercial operations.
  • Cash & restricted cash balances grew by 6% to $11.5 million CAD as of April 30, 2026.
  • The discovery platform has contributed to 20+ molecules reaching clinical trials, supported by over 400 peer-reviewed publications & issued patents.